NEWS HIGHLIGHTS
Published Studies Related to Covera-HS (Verapamil)
Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. [2009.07]
AIM: The aim of the present study is to evaluate the effect of treatment with verapamil, trandolapril and their combination on peripheral microcirculation vasoreactivity... CONCLUSION: The present study demonstrates that chronic treatment with verapamil ameliorates endothelial function in the forearm microcirculation of essential hypertensive patients, while trandolapril protects microcirculation from structural alterations. The combination of the two drugs is potentially a powerful tool to counteract hypertension-related microvascular dysfunction and damage.
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. [2009.06]
CONCLUSION: In CAD patients with hypertension, PP (on anti-hypertensive treatment) is a weaker predictor of cardiovascular outcomes than SBP, DBP, or MAP.
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. [2009.05]
AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate... CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.
Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. [2009]
PURPOSE: We aimed to assess the effect of intralesional verapamil on the treatment of Peyronie's disease... CONCLUSION: Although in some studies verapamil has been found to be effective in the treatment of Peyronie's disease, we did not find any improvement in comparison with the control group. Furthermore, larger scale studies are warranted to assess the effect of this drug on the treatment of Peyronie's disease.
Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. [2008.12]
OBJECTIVES: Attenuation of protein kinase C (PKC) is a mechanism common to both established (lithium, valproate) and some novel (tamoxifen) antimanic agents. Verapamil, although primarily known as a calcium channel blocker, also has PKC inhibitory activity. Verapamil has shown antimanic activity in some but not all studies. Therefore, we investigated verapamil, used alone or as an adjunctive treatment, in manic patients who did not respond to an initial adequate trial of lithium... CONCLUSIONS: In this preliminary investigation, verapamil monotherapy did not demonstrate antimanic efficacy. By contrast, the combination of verapamil plus lithium was highly efficacious. Our findings thus suggest that verapamil may have potential utility as an adjunct to lithium. This effect may be mediated by additive actions on PKC inhibition, which may be an important mechanism for antimanic agents in general.
Clinical Trials Related to Covera-HS (Verapamil)
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]
We, the researchers at the Indiana University School of Medicine, are doing this study to
better understand how the effects of certain medications are altered when taken
simultaneously, or in combination with each other. We will also look at how each volunteer's
genes (DNA) may affect the way these medications are metabolized.
Hypothesis:
We will test the hypothesis that the extent of drug-drug interaction caused by the
combination of erythromycin and diltiazem is not predictable from the extent of interaction
produced by each inhibitor alone. Specifically we will test the hypothesis that the
combination of erythromycin and diltiazem will cause a greater decrease in midazolam
intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.
INVEST: INternational VErapamil SR Trandolapril STudy [Completed]
Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is
important to keep it as normal as possible. There are several different ways to control
blood pressure and to prevent or limit the development of heart disease due to high blood
pressure. The purpose of this study is to compare two treatments to see how well they work
and the difference in their side effects. One treatment includes the use of a calcium
antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment
excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta
blocker (Tenormin or Atenolol). Both treatments may also include medication called
angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this
study are experimental, they are all approved by the Food and Drug Administration (FDA).
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem [Recruiting]
This is a pilot clinical study to assess whether the administration of diltiazem may be able
to decrease the development or progression of hypertrophic cardiomyopathy (HCM). Diltiazem
is a commonly used medication for the treatment of high blood pressure and studies on
animals with HCM suggest that diltiazem decreases disease development. This study
specifically targets individuals in the "prehypertrophic" phase of HCM-- those with
documented sarcomere gene mutations without echocardiographic or EKG evidence of LVH.
The hypothesis of this study is that starting diltiazem administration early in life (in the
prehypertrophic phase) will decrease the progression of HCM in individuals with sarcomere
gene mutations. This will be assessed by looking at an improvement in the heart's ability to
relax using echocardiography.
Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy [Recruiting]
Accumulated clinical and experimental data suggest that dysfunctional coronary
microcirculation plays a pivotal role in the progression of heart failure despite an optimal
therapy used. Therefore, we hypothesize that improvement in microvascular function by
calcium antagonist, verapamil may result in additional clinical benefit. Thus, the aim of
this study is to compare the effect of treatment with verapamil or carvedilol on long-term
outcomes in stable, chronic heart failure secondary to non-ischemic cardiomyopathy.
Therapy With Verapamil or Carvedilol in Chronic Heart Failure [Recruiting]
The aim of this study is to compare the effect of treatment with verapamil or carvedilol on
long-term outcomes in stable, chronic heart failure secondary to non-ischemic
cardiomyopathy.
|
